SCHEMBL20543509

SCHEMBL20543509

O=c1c(Cc2ccccc2)nc2c(Cc3ccccc3F)[nH]c(-c3ccccc3)cn1-2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.37
▸ PDE3B Q13370 1/20 0.36
▸ PDE3A Q14432 1/20 0.36
▸ MAPT P10636 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ AR P10275 1/20 0.34
▸ POLB P06746 2/20 0.34
▸ CES2 O00748 1/20 0.34
▸ CTSB P07858 1/20 0.34
▸ TOP2A P11388 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ HPGD P15428 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20543506 0.96 GAA (0.37) GAAPDE3BPDE3AMAPTALDH1A1
SCHEMBL20548364 0.93 GAA (0.35) GAAPDE3BPDE3AMAPTALDH1A1
SCHEMBL20543577 0.91 THRB (0.38) GAAPDE3BPDE3AMAPTALDH1A1
SCHEMBL24027401 0.89 PDE3B (0.35) GAAPDE3BPDE3AMAPTALDH1A1
SCHEMBL492636 0.89 LTB4R (0.41) GAAMAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL20543328 0.88 ALDH1A1 (0.36) GAAPDE3BPDE3AMAPTALDH1A1
SCHEMBL20543625 0.88 GNRHR (0.40) ALDH1A1NPC1RAB9ALMNAMEN1
SCHEMBL16154083 0.87 ADORA3 (0.38) GAAMAPTALDH1A1NPC1RAB9A
SCHEMBL20543416 0.86 NPC1 (0.33) GAAPDE3BPDE3AMAPTALDH1A1
SCHEMBL20543580 0.86 MAPT (0.35) GAAPDE3BPDE3AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3964501-B1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS PASTEUR INSTITUT (FR) 2024-09-04 — — EP claimed
US-20240197923-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2024-06-20 — — US claimed
EP-3964501-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2022-03-09 — — EP claimed
US-20200129644-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2020-04-30 — — US claimed
EP-3395803-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS Institut Pasteur (FR) 2018-10-31 — — EP claimed
US-12612411-B1 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins INSTITUT PASTEUR (FR) 2026-04-28 — — US disclosed
US-12576164-B2 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins INSTITUT PASTEUR (FR) 2026-03-17 — — US disclosed
US-20240361321-A1 LUMINESCENT BASED ANTIGEN ASSAY INSTITUT PASTEUR (FR) 2024-10-31 — — US disclosed
EP-3964501-B1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS PASTEUR INSTITUT (FR) 2024-09-04 — — EP disclosed
EP-4392460-A1 LUMINESCENT BASED ANTIGEN ASSAY Institut Pasteur (FR) 2024-07-03 — — EP disclosed
US-20240197923-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2024-06-20 — — US disclosed
CN-118139895-A Luminescence-based antigen assay 巴斯德研究所 2024-06-04 — — CN disclosed
EP-3615516-B1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS PASTEUR INSTITUT (FR) 2021-11-17 — — EP disclosed
EP-3615516-B1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS PASTEUR INSTITUT (FR) 2021-11-17 — — EP disclosed
EP-3904508-A1 LUCIFERASE LINKED IMMUNOSORBENT ASSAY Institut Pasteur (FR) 2021-11-03 — — EP disclosed
US-20200129644-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2020-04-30 — — US disclosed
US-20200129644-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2020-04-30 — — US disclosed
EP-3615516-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS Institut Pasteur (FR) 2020-03-04 — — EP disclosed
WO-2018197727-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2018-11-01 — — WO disclosed
EP-3395803-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS Institut Pasteur (FR) 2018-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200129644-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS NISCH, HLCS, CYP3A5 GAA 2507/4885PDE3B 448/4885PDE3A 439/4885
US-12576164-B2 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins LUC7L2, HLCS, LANCL1 GAA 1912/4885PDE3B 1467/4885PDE3A 1169/4885
US-12612411-B1 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins LUC7L2, MRPL21, CRY1 GAA 4623/4885PDE3B 733/4885PDE3A 492/4885
US-20240197923-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS NISCH, HLCS, CYP3A5 GAA 2507/4885PDE3B 448/4885PDE3A 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback